Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) p
- 作者：Bensmaï ; ne ; M.A. ; de Gramont ; A. ; Brienza ; S. ; Marty ; M. ; Lé ; vi ; F. ; Ducreux ; M. ; Franç ; ois ; E. ; et. al.
- 关键词：Clinical resistance ; Multivariate analysis ; Salvage chemotherapy
- 刊名：European Journal of Cancer
- 出版年：2000
- 期刊代码：88_09598049
- 类别：med
- 出版时间：December, 2000
- 卷：36
- 期：1
- 页码：2335-2343
- 文件大小：155 K
摘要
Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin®)/5-FU±folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment. The response rate was 14.6%(95%confidence interval (CI): 11.0–18.2%), median time to progression was 4.3 months (95%CI: 3.9–4.7), and median overall survival 9.7 months (95%CI: 8.5–10.8). Multivariate analysis indicated <2 prior chemotherapy regimens, bi-weekly treatment administration schedule (versus tri-weekly) and continuous chronomodulated delivery (CCM) as significantly associated (P<0.05) with a higher overall response rate. Performance status (PS) <2, having only one involved organ, biweekly schedule and CCM were associated (P<0.05) with a longer time to progression. Good PS, one involved organ, low alkaline phosphatase (AP) serum levels, bi-weekly schedule and CCM were significantly correlated with longer overall survival, while confirming the efficacy of oxaliplatin/5-FU±FA in this indication.